Sales Accounting

Larry A. May

***** ******** **, *********, ** ***12 805-***-**** (

abhclh@r.postjobfree.com

Chief Financial officer

M&A's / P&L / JV's / Board Presentations / Treasury / US & International

Accounting / SOX / SEC / Budgets

Due Diligence / IPO / Startups / Business Systems / Banking & Investor

Relations / Planning & Forecasting

Driving financial operations for startups, small, and multi-billion dollar

public companies (Amgen), I was successful as a key thought leader in

identifying and capitalizing on opportunities to improve financial

integrity and increase shareholder value. As a member of the Executive

Team, I provided sound guidance for executive decision-making.

o Defining business models/finance, analytical, reporting and planning

systems to support growth

o Applying multiple strategies to raise capital from diverse sources

o Restructuring and re-engineering budget and financial processes to

improve efficiency

o Providing due diligence and preparing documentation for M&A's, IPO's,

SEC and SOX reporting

o Leading local and globally dispersed teams to ensure timely/accurate

filings and reporting

I earned a BS in Business Administration/Accounting from the University of

Missouri and started my career as a CPA/Auditor with Arthur Andersen & Co.

in Mo. Known for my analytical approach; I easily differentiate strategic

needs from tactical or unnecessary efforts. Calm under pressure, I can meet

exacting deadlines and objectives.

Highlighted Accomplishments

Identified strategic cellular therapy technology and negotiated licenses.

In 2007 NeoStem initiated a program of in-licensing stem cell and cellular

therapy technology. I identified key cell therapy technology for closing

chronic wounds, directed patent searches to determine there were no

conflicting patents or alternative therapies, prepared financial model and

business plan to support the acquiring technology, negotiated license.

Negotiated two acquisitions, closing in 90 days. BioSource wanted to

acquire complementary products. Identified one company and CEO selected

another. Led process from due diligence to negotiating close, leading to

$7.5M added sales from BioFluids and new channel that added 5% growth to

existing products. Quality Biotech added $12M in sales.

Secured $30M line of credit. Publicly traded BioSource competed against

larger companies in Research Reagent space with money resources. Needed

cash resources to be creditable in our M&A initiatives. Negotiated with

Union Bank to obtain line of credit converted into loan as each deal was

completed, enabling company to complete two acquisitions in 90 days.

Introduced debt capital into company's capital structure. Amgen was

diluting its equity capital with employee stock option plan. Issued debt as

source of cash, funding stock repurchase program to offset dilution.

Negotiated with banks as underwriters. Enabled Amgen to register $500M in

corporate bonds/issue $100M in public offering.

$150M capital raise. Amgen sought more capital for R&D. Led senior

management team to analyze multiple options, deciding to pursue R&D limited

partnerships and common stock offering. Raised $75M as offering of common

stock and $75M from sale of R&D Limited Partnership units. Prepared

documents for SEC approval.

Redesigned budget process. Budget process at Amgen was dysfunctional.

Assembled team of 40 managers to discuss improvements. Outlined new process

with Finance establishing guidelines and profit targets. Improved budget

reliability and resource allocation, cut preparation time 50-75%, and

reduced organizational stress.

Career History

Chief Financial Officer, NeoStem, 2003 - Present. $70M global

biomedical/biotech/pharmaceutical company. Prepare documentation for SEC

and SOX compliance. Develop business plans/strategy. Conducted due

diligence for acquisition of China Biopharmaceutical Holdings, resulting in

51% interest in Eyre Pharmaceutical Co. Ltd.

CFO, Saronyx, Inc. 2001 - 2003. Developed business plans/strategy for

startup creating software/secure network for pre-clinical development

scientists. Presented business to VC's and other investors/clients.

CFO, BioSource International Inc., 1998 - 2000. Managed financial/IT

functions, investor/banking relations, technical services, label/packaging,

and purchasing for $30M research reagent product manufacturer with

manufacturing, distribution and sales operations in US and Europe. Prepared

10K's/10Q's for filing with SEC.

Vice President Treasurer, Amgen, 1997-1998. Managed $1.5B budget and 115

staff for $2.2B biotech company. Directed Credit/Collections, excess cash

investment, foreign exchange hedging and acquisition of debt, common stock

buyback program, and definition of company's capital structure. Responsible

for business systems/network.

VP Controller/Chief Accounting Officer, Amgen, 1983 - 1997. Directed all

US/foreign accounting operations including public reporting, financial

planning/forecasting, budgeting, and global business systems. Participated

in Amgen/Hoffman-LaRoche joint ventures Board. Managed 186 staff/$1.5B

budget.

Contact this candidate